Merck acquires Insmed’s portfolio of protein-based drugs and manufacturing facilities for US$130 M in a bid to accelerate its entry into the lucrative biosimilars market. To date, there is no regulatory pathway for the approval of biosimilars in the US and Merck is moving early so that it gains the necessary expertise and capabilities for when the regulatory process is in place.